The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Data from phase I/II open-label study of BCMA-directed CAR-T cell therapy lcar-b38m show tolerable safety profile, high response and MRD-negative rate in advanced r/r multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Janssen Pharmaceutical Companies of Johnson & Johnson reported updated results from Legend Biotech Inc.’s LEGEND-2 phase I/II open-label study, which evaluated the investigational chimeric antigen receptor T-cell therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory multiple myeloma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

USPSTF doesn’t lean right or left—it’s about data, not politics

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

By Barnett Kramer
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account